OncoACP3
Prostate Cancer
Pre-clinical/Phase 1Active (Licensed to RayzeBio/BMS)
Key Facts
Indication
Prostate Cancer
Phase
Pre-clinical/Phase 1
Status
Active (Licensed to RayzeBio/BMS)
Company
About Philochem
Philochem is a discovery-focused biotech subsidiary of the Philogen group, leveraging its leadership in DNA-encoded chemical libraries and phage display to create novel targeted anti-cancer therapies. The company has demonstrated significant validation through a major licensing deal with RayzeBio/Bristol Myers Squibb for its prostate cancer radiopharmaceutical program, OncoACP3, valued at up to $1.35 billion plus royalties. With a strategy centered on ligand-based pharmacodelivery to spare healthy tissues, Philochem advances a pipeline of small molecule therapeutics, antibodies, and radiopharmaceuticals from discovery into clinical development.
View full company profileTherapeutic Areas
Other Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO442 | Aptevo Therapeutics | Preclinical |
| APVO452 | Aptevo Therapeutics | Discovery |
| BIO 300 | Humanetics Corp. | Not Specified |
| Opaganib | RedHill Biopharma | Phase 2 |
| MagSense™ PSMA Imaging Agent | Imagion Biosystems | Pre‑clinical |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| Leronlimab | CytoDyn | Preclinical |
| CROES Registry | AngioDynamics | Post-Market Registry |
| Cannabics® PRST-33 | CNBX Pharmaceuticals | Discovery |
| HDP-103 | Heidelberg Pharma | Preclinical |
| ENV105 | Kairos Pharma | Phase 2 |
| AI for Prostate Cancer | Invenio Imaging | Research |